Who said rush? You. I'll repeat slowly: had the company been 100% focused on IDE instead of what seems to be more than 50% of their time and effort over last 2 years focused on IsoPet, I am saying this last round of dilution wouldn't have been necessary. Why? Because the testing would have been started sooner and finished sooner. They have minimal staffing, which is good, but it hurts them when they try to push 2 divisions forward at the same time.
I will use this as an opportunity to buy more shares, but I would MUCH rather have our price at 20 cents + and the testing and analysis done months ago. Who knows how much higher the price would be now if they were focused on what matters most (IDE).
It is what it is...
News 
Market Data 
Discover 
AI
